ClinicalTrials.gg
CompletedNCT05497557Updated Jan 19, 2024Results posted

A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers

A Phase 1 interventional study of Omeprazole and Sotorasib in Healthy Volunteers, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-19.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate the effects of omeprazole (a proton-pump inhibitor) and an acidic beverage (Coca-Cola) on sotorasib pharmacokinetics (PK) when administered orally in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
  • Sotorasib
  • AMG 510
  • Omeprazole
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male participants or female participants, between 18 and 60 years of age (inclusive), at the time of Screening.
  • , between 18 and 30 kg/m\^2 (inclusive), at the time of Screening.
  • Females of nonchildbearing potential.

Exclusion criteria

Exclusion:

  • Inability to swallow oral medication or history of malabsorption syndrome.
  • History of , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
  • Poor peripheral venous access.
  • History or evidence, at Screening or Check in, of disorder, condition, or disease, including history of myolysis, not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Omeprazole + Sotorasib

    Drug: Omeprazole · Drug: Sotorasib

Interventions

  • Omeprazole will be administered as an oral capsule.

  • Sotorasib will be administered as an oral tablet.

    Also known as: AMG 510

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Days 1 and 9

  2. Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Days 1 and 9

  3. Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) of Sotorasib

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Days 1 and 9

Secondary outcomes

  1. Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

    An adverse event is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. A TEAE was defined as an adverse event that starts during or after the first dose, or starts prior to the first dose and increases in severity after the first dose. Any clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms and vital signs were recorded as an adverse event.

    Time frame: Day 1 to Day 11

07

Results

Posted Jan 19, 2024

Participant flow

16 participants were enrolled at 1 center in the United States.

Period 1: Sotorasib Alone
Participant flow — Period 1: Sotorasib Alone
MilestoneSotorasib AloneOmeprazole AloneOmeprazole Co-administered With Sotorasib
Started1600
Completed1600
Not completed000
Period 2: Omeprazole Alone
Participant flow — Period 2: Omeprazole Alone
MilestoneSotorasib AloneOmeprazole AloneOmeprazole Co-administered With Sotorasib
Started0160
Completed0140
Not completed020
Withdrew: Withdrawal by subject020
Period 3: Omeprazole With Sotorasib
Participant flow — Period 3: Omeprazole With Sotorasib
MilestoneSotorasib AloneOmeprazole AloneOmeprazole Co-administered With Sotorasib
Started0014
Completed0014
Not completed000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Days 1 and 9
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Sotorasib
ng/mLSotorasib AloneOmeprazole Co-administered With Sotorasib
Maximum Observed Plasma Concentration (Cmax) of Sotorasib7160 ± 22.94850 ± 65.6
Statistical analysis
  • Sotorasib Alone vs Omeprazole Co-administered With Sotorasib · Ratio of geometric least squares mean: 0.677 · 90% CI 0.547 to 0.839
PrimaryArea Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Days 1 and 9
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Sotorasib
h*ng/mLSotorasib AloneOmeprazole Co-administered With Sotorasib
Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Sotorasib30200 ± 33.323500 ± 60.4
Statistical analysis
  • Sotorasib Alone vs Omeprazole Co-administered With Sotorasib · Ratio of geometric least squares mean: 0.771 · 90% CI 0.628 to 0.948
PrimaryArea Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) of Sotorasib
Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Days 1 and 9
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) of Sotorasib
h*ng/mLSotorasib AloneOmeprazole Co-administered With Sotorasib
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-tlast) of Sotorasib30000 ± 33.323200 ± 62.2
Statistical analysis
  • Sotorasib Alone vs Omeprazole Co-administered With Sotorasib · Ratio of geometric least squares mean: 0.766 · 90% CI 0.619 to 0.948
SecondaryNumber of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

An adverse event is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. A TEAE was defined as an adverse event that starts during or after the first dose, or starts prior to the first dose and increases in severity after the first dose. Any clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms and vital signs were recorded as an adverse event.

Time frame:
Day 1 to Day 11
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
ParticipantsSotorasib AloneOmeprazole AloneOmeprazole Co-administered With Sotorasib
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)020

Adverse events

Collected over Day 1 to Day 11. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotorasib Alone0/16 (0%)0/16 (0%)0/16 (0%)
Omeprazole Alone0/16 (0%)0/16 (0%)2/16 (12.5%)
Omeprazole Co-administered With Sotorasib0/14 (0%)0/14 (0%)0/14 (0%)
Most frequent other events
Most frequent other events
EventSotorasib AloneOmeprazole AloneOmeprazole Co-administered With Sotorasib
ConstipationGastrointestinal disorders0/161/160/14
HeadacheNervous system disorders0/161/160/14
SyncopeNervous system disorders0/161/160/14

Baseline characteristics

Baseline characteristics are presented in the All Subjects Population, which included all participants who signed the informed consent form and had any study assessment recorded in the database per the protocol.

Age, Continuous
Age, Continuous(years)Sotorasib and Omeprazole: All Participants
Mean36.7 ± 10.18
Sex: Female, Male
Sex: Female, Male(Participants)Sotorasib and Omeprazole: All Participants
Female2
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sotorasib and Omeprazole: All Participants
Hispanic or Latino3
Not Hispanic or Latino13
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sotorasib and Omeprazole: All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American11
White3
More than one race1
Unknown or Not Reported0
08

Study locations

1 site
  • Labcorp Clinical Research Unit Inc.
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Sep 2022, 1 month.

Results were first posted in Jan 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2022
First posted
Aug 11, 2022
StartActual
Jul 14, 2022
Primary completionActual
Sep 8, 2022
CompletionActual
Sep 8, 2022
Results first posted
Jan 19, 2024
Last update
Jan 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05497557
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 11, 2022
Start date
Jul 14, 2022
Primary completion
Sep 8, 2022
Completion
Sep 8, 2022
Results posted
Jan 19, 2024
Last update
Jan 19, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Omeprazole · Sotorasib

Start the discussion